Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 85

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 85
---
 information regarding any option exercises during the fiscal year ended December 31, 2024, with respect to our named executive officers. No shares were acquired during the fiscal year ended December 31, 2024, by our named executive officers pursuant to the vesting of stock awards.

|                 |     | Option Awards |     |             |
| Name            |     |     Number of 
        Shares 
      Acquired 
   on Exercise 
           (#) |     |       Value 
    Realized 
 on Exercise 
      ($)(1) |
| Bahija Jallal   |     |             — |     |           — |
| Brian Di Donato |     |             — |     |           — |
| David Berman    |     |       120,000 |     |   6,209,484 |
| Tina St. Leger  |     |         8,750 |     |     323,663 |

| (1) | The value realized on exercise is based on the closing price of our ADSs on Nasdaq on the date of exercise minus the exercise price and does not reflect actual proceeds received. |

Employment Arrangements with our Named Executive Officers We have entered into employment agreements or contracts, as applicable, with each of our named executive officers. The agreements set forth the terms and conditions of each executive’s employment with us, including base salary, bonus opportunity, eligibility for employee benefits and severance benefits upon a qualifying termination of employment, and certain non-solicitation and non-competition provisions. Any potential payments and benefits due upon a qualifying termination of employment or a change in control are further described below under “—Potential Payments and Benefits upon Termination or Change in Control.” The employment of each of our named executive officers (other than Ms. St. Leger) may be terminated at any time in accordance with the terms of the respective agreements. Ms. St. Leger’s employment may only be terminated in accordance with her employment contract, which includes six months’ notice. In addition, each of our named executive officers has executed a form of our standard proprietary information and inventions agreement. The material terms of each agreement are described below.

57

TABLE OF CONTENTS Bahija Jallal, Ph.D. In January 2021, we and our United States subsidiary, Immunocore, LLC, entered into an amended and restated employment agreement with Dr. Jallal, which became effective on February 4, 2021, upon the execution of the under